Influence of B Cell Depletion By Monoclonal Anti CD20 Antibodies in Systemic Sclerosis: Results of a Randomized Placebo Controlled Trial

被引：0
|
作者：
Ben Said-Bouyeri, Samira [1 ]
Meijs, Jessica [1 ]
Marsan, Nina Ajmone [2 ]
Schouffoer, Anne A. [1 ]
Ninaber, Maarten K. [3 ]
Scherer, Hans Ulrich [4 ]
Bonte-Mineur, Femke [5 ]
Huizinga, T. W. J. [1 ]
de Vries-Bouwstra, Jeska K. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Cardiol, Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Pulmonol, Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands
[5] Maasstad Hosp, Rotterdam, Netherlands
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
836
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Anti-CD20 monoclonal antibodies in multiple sclerosis
    Moreno Torres, Irene
    Garcia-Merino, Antonio
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (04) : 359 - 371
  • [12] B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies
    K Bojarczuk
    M Siernicka
    M Dwojak
    M Bobrowicz
    B Pyrzynska
    P Gaj
    M Karp
    K Giannopoulos
    D G Efremov
    C Fauriat
    J Golab
    M Winiarska
    Leukemia, 2014, 28 : 1163 - 1167
  • [13] B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies
    Bojarczuk, K.
    Siernicka, M.
    Dwojak, M.
    Bobrowicz, M.
    Pyrzynska, B.
    Gaj, P.
    Karp, M.
    Giannopoulos, K.
    Efremov, D. F.
    Fauriat, C.
    Golab, J.
    Winiarska, M.
    LEUKEMIA, 2014, 28 (05) : 1163 - 1167
  • [14] Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies
    Bojarczuk, Kamil
    Winiarska, Magdalena
    Bobrowicz, Malgorzata
    Dwojak, Michal
    Miazek, Nina
    Zapala, Piotr
    Efremov, Dimitar G.
    Golab, Jakub
    BLOOD, 2013, 122 (21)
  • [15] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    Arthritis Res Ther, 5
  • [16] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    Eisenberg, R
    Albert, D
    Stansberry, J
    Tsai, D
    Kolasinski, S
    Khan, S
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
  • [17] Synergistic cell death elicited with CD20 monoclonal antibodies and vorinostat
    Nolan, Luke
    Crabb, Simon
    Beers, Stephen
    Wakelin, Rachel
    Donlevy, Alison
    Mitter, Richard
    Cragg, Mark
    Glennie, Martin
    Johnson, Peter
    Packham, Graham
    CANCER RESEARCH, 2009, 69
  • [18] B cell depletion by CD20 immunotherapy inhibits skin fibrosis and autoimmunity in tight-skin mice, a model for systemic sclerosis
    Hasegawa, M
    Sato, S
    Hamaguchi, Y
    Uchida, J
    Takehara, K
    Tedder, TF
    FASEB JOURNAL, 2005, 19 (04): : A926 - A926
  • [19] Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
    Shan, D
    Ledbetter, JA
    Press, OW
    BLOOD, 1998, 91 (05) : 1644 - 1652
  • [20] Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus
    Shah, Kavina
    Cragg, Mark
    Leandro, Maria
    Reddy, Venkat
    BIOLOGICALS, 2021, 69 : 1 - 14
12345